Endogenous bufadienolides, mineralocorticoid receptor antagonists and fibrosis in chronic kidney disease

Area of Science:

• Nephrology
• Cardiology
• Molecular Biology

Background:

• Chronic kidney disease (CKD) is a major cause of premature death, primarily due to cardiovascular (CV) complications.
• Current treatments for CKD can only slow disease progression, emphasizing the need for early diagnosis and novel therapies.

Purpose of the Study:

• To review recent advancements in understanding the fibrotic basis of CKD and its link to cardiovascular disease.
• To highlight novel biomarkers for early CKD detection and risk stratification.
• To discuss emerging therapeutic strategies targeting the fibrotic pathway.

Main Methods:

• Literature review of recent research on CKD pathogenesis and biomarkers.
• Analysis of the role of the Na/K-ATPase system and its endogenous ligands in fibrosis.
• Examination of novel treatment approaches, including mineralocorticoid receptor antagonists.

Main Results:

• Novel biomarkers such as PIIINP, PICP, FGF23, marinobufagenin, and miRNAs show potential for early CKD detection and risk stratification.
• The "fibrotic concept" implicates the Na/K-ATPase system and marinobufagenin in CKD and vascular collagen synthesis.
• Mineralocorticoid receptor antagonists demonstrate efficacy in impairing marinobufagenin-Na/K-ATPase interactions, offering a new treatment avenue.

Conclusions:

• Advances in understanding CKD's fibrotic etiology are paving the way for improved diagnostics and therapeutics.
• Targeting the marinobufagenin-Na/K-ATPase pathway represents a promising strategy for managing CKD and its cardiovascular sequelae.